International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1587-1602 www.ijprajournal.com ISSN: 2456-4494

Antifungals:Effective Treatments for Fungal Infections

Rukesh Kumar Sharma[1], Parul Verma[2], Kiran Bala[3],Ajeet Pal Singh[4] &Amar Pal Singh[5]

St.SoldierInstituteofPharmacy, Lidhran Campus, Behind NIT (R.E.C), Jalandhar -Amritsar By Pass Nh-1, Jalandhar 144011, Punjab, India

Date of Submission: 05-04-2025 Date of Acceptance: 15-04-2025

ABSTRACT:
Antifungal agents are medications used to treat infections caused by fungi, which can affect various parts of the body, including the skin, nails, respiratory system, and internal organs. These infections range from superficial conditions, such as athlete's foot and ringworm, to more severe, systemic illnesses like candidiasis and aspergillosis. Antifungals work by targeting the cell structures and functions of fungi, inhibiting their growth or killing them.There are several classes of antifungal agents, each with distinct mechanisms of action. The most common categories include azoles, polyenes, echinocandins, and allylamines. Azoles, such as fluconazole and itraconazole, inhibit the synthesis of ergosterol, a critical component of fungal cell membranes. Polyenes, including amphotericin B, bind to ergosterol and disrupt the cell membrane, leading to fungal cell death. Echinocandins, like caspofungintarget fungal cell wall synthesis, while allylamines, such as terbinafine, inhibit enzymes responsible for ergosterol production.Antifungal therapy can be administered topically, orally, or intravenously, depending on the severity and location of the infection. Topical treatments are typically used for skin and nail infections, while oral and intravenous antifungals are reserved for more severe or systemic fungal infections. However, antifungal resistance is a growing concern, as fungi can develop resistance to these drugs, making treatment more challenging. In conclusion, antifungal drugs are vital tools in the management of fungal infections, with a variety of classes targeting different aspects of fungal biology. Ongoing research into new antifungal agents and strategies is essential to address the rising challenge of resistance and improve patient outcomes.

Keyword: Antifungal, Aspergillus fumigatus, Candidiasis, Histoplasmosis, onychomycosis.

I. INTRODUCTION:

A fungal infection occurs when harmful fungi invade the body. Fungi are microorganisms that can live in the environment or inside the body. While some fungi are harmless or even beneficial,otherscancause infectionswhentheygrowuncontrollablyorwhenthei mmune system is weakened. Fungal infections can affect different parts of the body.Every year, invasive fungal infections cause 1.7 million deaths worldwide. They occur frequently in people with immune deficiencies, as evidenced by their organ transplantation, acquired immune deficiency syndrome, and/or chemotherapy. The yearly incidence of harmful There are more than 300,000 instances of aspergillosis, 750,000 cases of candidiasis, and 10,000 cases of mucormycosis, respectively.

When Indian data estimations are taken into account, the annual incidence of this condition can exceed 900,000 cases. Moreover, there is a major death risk linked to these illnesses. Invasive fungal infection epidemiology often concentrates on particular regions.



Fig(1): Fungal Infection

The mortality rates for invasive aspergillosis and candidiasis vary greatly, ranging from 30% to 95% and 46% to 75%, respectively, due to a lack of global statistics.Different fungal cell components are the focus of these classes.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1587-1602 www.ijprajournal.com ISSN: 2456-4494

First, ergosterol, the primary component of the fungal cell membrane, interacts with the heptaene amphotericin B (AMB), which is a member of the polyene class.one to six incidences of widespread scedosporiosis and fusariosis are reported for every 1000 patients of hematopoietic stem cell transplants. For systemic therapy, doctors and health professionals now employ four kinds of antifungal medications. Different sections of the fungal cell are the focus of these classes. First, the heptaene amphotericin B (AMB), which is a member of the polyene family, interacts with ergosterol, the primary component of the fungal membrane of a cell. AMB exhibits strong fungicidal properties against Aspergillus fumigatus, A. flavus, and Candida species . Second, the lanosterol demethylation phase of ergosterol biosynthesis is harmed by triazoles of the first and second generations. Triazoles often have a fungistatic effect on yeasts but a fungicidal effect on Aspergillus species.Echinocandins prevent the fungal cell wall's d-glucans from being synthesized. Aspergillus and Candida species are susceptible to the fungicidal and fungistatic effects of echinocandins, respectively. Lastly, flucytosine (5-FC), a pyrimidineanalogue, interacts with the nucleusof the fungus, affecting the production of proteins and deoxyribonucleic acid (DNA). Opportunistic pathogen resistance rises when antifungal medications are overused. This kind of antibiotic resistance has been recognized by the World Health Organization as one of the main risks for 2019. This publication did not address immunomodulatory therapy which include both molecular and cell-based treatments. Similarly, the use of therapeutic enzymes or mycoviruses to break down fungal cell wall constructions or biofilms has not been covered in this communication and has been covered elsewhere.We examined the key authorized and chosen experimental antifungal medications in this paper This publication did not address immunomodulatory therapy, which include both molecular and cell-based treatments.

ANTI FUNGAL:

An antifungal is a type of medication used to prevent or treat fungal infections by inhibiting the growth of fungiorkilling them.These drugs target fungal structures such as the cell membrane,cell wall, ormetabolic path ways, which are different from those in human cells.

CAUSE OF FUNGAL INFECTION:

Overgrowth or invasion of the body by fungus can result in fungal infections. The environment is naturally home to fungi, and some of them can even survive on human bodies without harming people. Infections, however, might result from certain circumstances.

SIGN AND SYMPTOMS

Fig(2): Symptoms & Sign of Fungal Infection

TYPES OF ANTI FUNGAL MEDICATIONS:

Pharmacology and Toxicity of Antifungal Agents

Due to its limited water solubility, amphotericin B is linked to sodium deoxycholate in the medication formulation. Following intravenous injection, AMB binds to plasma lipoproteins, separates from deoxycholate, and builds up in the liver and spleen. AMB has an elimination half-life of more than 15 days. It is not broken down by CYP450 enzymes and is instead eliminated as an unaltered medication in the urine (33%) and feces (43%). The toxicity of AMB deoxycholate, both infusion- and dose-related, is one of its fundamental drawbacks. The activation of pro-inflammatory cytokines and chemokines, including interleukin 1β, tumor necrosis factor α, monocyte chemotactic protein 1, and macrophage inflammatory protein, is the cause of the infusion-related toxicity.5-flucytosine, on the other hand, is a tiny hydrophilic molecule that absorbs quickly and has a nearly 90% bioavailability. 5-FC is barely metabolized by liver enzymes. Its plasma clearance is as quick as creatinine clearance, and it is completely removed via glomerular filtration, which has strong antifungal activity in the bladder. Because 5-FC has a half-life of up to four hours, it is dosed often. Because susceptible cells use the same transport mechanism, 5-FC's antifungal action is competitively inhibited when administered with cytarabine, a medication that effectively treats acute myeloid leukemia. Hepatotoxicity,

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1587-1602 www.ijprajournal.com ISSN: 2456-4494

myelotoxicity, and gastrointestinal issues are examples of severe adverse effects.

Topical Antifungals:

Topical anti fungals are drugs used to treat fungal infections that are applied directly to the skin, nails, or mucous membranes. By destroying fungus or inhibiting their growth, these drugs halt the infection from spreading.

Treatment of fungal infection

Antifungal drugs are used to treat fungal infections by either killing the fungus or prevent ingits growth.The kind, extent, and location of the infection determine the course of treatment.

Treatment Based on Type of Fungal Infection

Superficial Fungal Infections (Skin, Hair, and Nails)

1.Ringworm, Athlete's Foot, JockItch→Topical antifungals (Clotrimazole, Terbinafine) for mild cases; Oralantifungals for severe infections.
2.Nail Fungus(Ony chomycosis)→Oral terb in a fine oritraconazole (6-12 weeks); topical solutions for mild cases.
3.Yeast Infections (Candidiasis –mouth, vagina, skin folds)→Fluconazole (oral) or Clotrimazole (topical).
Systemic Fungal Infections(Affecting Internal Organs)
4.Lung Infections (Histoplasmosis, Aspergillosis, Coccidioidomycosis)→Itraconazole or Amphotericin B(IV for severecases).
5.Blood stream Infections (Candidemia, Cryptococcal Meningitis)→Echinocandins (Caspofungin, Micafungin) or Amphotericin B.

1.Azoles (Inhibit Ergosterol Synthesis)

Imidazole, Clotrimazole, Miconazole, Ketoconazole, Econazole, Tioconazole, Oxiconazole, Sulconazol, Triazoles, Fluconazole (rarely used topically), Itraconazole (rarely used topically), Allylamine ,Benzylamines (Inhibit Squalene Epoxidase), Allylamines, Terbinafine, Naftifine, Benzylamines

2.Polyenes (Bindto Ergosterol, Causing Membrane Disruption)

Nystatin, Amphotericin B (rarely used topically), Echinocandins (Inhibit β-Glucan Synthesis)
Caspofungin (not commonly used topically)

3.Other Topical Antifungals

Pyridone Derivatives, Ciclopirox, Thiocarbamates, Tolnaftate, Undecylenic Acid and Its Salts Undecylenic acid

Azoles:

Azolesarea class of antifungal medications that function by preventing the formation of ergosterol, a crucial component of fungal cell membranes, by blocking the cytochrome P450 enzymelanostero l14α-demethylase. This results in increased membrane permeability and fungal cell death.

TypesofAzoles

Azoles are divided into two maingroups based on their chemical structure:

1.Imidazoles (Contain Two Nitrogen Atomsinthe Azole Ring)

Clotrimazole, Miconazole, Ketoconazole, Econazole Tioconazole Oxiconazole Sulconazole. These are Mostly used topically for superficial fungal infections (e.g., athlete's foot, ringworm, candidiasis).
2.Ketoconazole can also be used systemically, but its oral use is limited due to liver toxicity.

Triazoles, Itraconazole, Voriconazole, Posaconazole, Isavuconazole, Triazoleshave broader antifungal activity and are often used systemically for serious fungal infections, including candidiasis, aspergillosis, and cryptococcal meningitis. Fluconazoleis also available intopical formulations for localized infection.

Mechanism of Action:

Azoles exert their antifungal effects primarily by inhibiting the synthesis of **ergosterol**, a crucial component of the fungal cell membrane.Here's a more detailed breakdown of their action:

Target Enzyme: Lanosterol 14α-Demethy lase (CYP450enzyme) Azoles specifically inhibit the lanosterol 14α-demethylaseenzyme, which is a cytochrome P450 enzyme. This enzymeis involved in the conversion of lanosterol (aprecursormolecule) to ergosterol, a key component of the fungal cell membrane. Disruption of Ergosterol Production By inhibiting lanosterol 14α-demethylase, azolesprevent the proper synthesis of ergosterol. Ergosterolis essential for

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1587-1602 www.ijprajournal.com ISSN: 2456-4494

maintaining the integrity and fluidity of the fungal cell membrane

Consequences of Ergosterol Deficiency
Membrane Instability:
Without ergosterol, the fungal cell membrane becomes leaky and fragile.

Disrupted Membrane Function:
The cell membrane's permeability increases, causing loss of essential intracellular components (like ions, proteins, etc.), ultimately leading to cell death.

Increased Susceptibility:
The loss of ergosterol also interferes with the function of membrane-bound enzymesand transporters, weakening the cell's overall function and replication capabilities. Fungistaticor Fungicidal Effect At lower concentrations, azoles can be fungistatic, meaning they stop the growth and replication of the fungus. At higher concentrations, they canbe fungicidal, meaning they directlykill the fungal cells.

Drugs:.
Clotrimazol:
A synthetic imidazole with a wide range of antimycotic action is clotrimazole.An FDA-approved medication called clotrimazole is used to treat dermatomycoses, vulvovaginal candidiasis, and oral candidiasis. Pityriasis versicolor, ringworm, athlete's foot, jock itch, intertrigo, and erythrasma are amongthe skin illnesses that thismedication effectively treats.

Furthermore, at very high doses, clotrimazole exhibits activity against Trichomonas species and moderate activity against certain gram-positive bacteria. The FDA has authorized the topical treatment of inflammatory tinea caused by Epidermophyton floccosum and Trichophyton in adults and children over the age of twelve by using clotrimazole in conjunction with betamethasone propionate, a corticosteroid. However, as certain combinations can exacerbate fungal infections, care should be taken.

Mechanism of action:
The main way that clotrimazole works is by rupturing the fungal cytoplasmic membrane's permeability barrier. By preventing 14-α-lanosterol from being demethylated, clotrimazole limits the manufacture of ergosterol in a concentration-dependent manner.The cell can no longer create a functional and unbroken cell membrane when ergosterol synthesis is suppressed.Because ergosterol also directly stimulates fungal cell development in a manner similar to that of hormones, the quick commencement of these processes results in a dose-dependent suppression of fungal growth.Clotrimazole suppresses ergosterol production to have its antifungal effect, but it also has additional pharmacological effects.

Pharmacokinetics:
Oral: Clotrimazole oral lozenges don't show much bioavailability and are only used for local therapy. It seems that clotrimazole's adherence to the oral mucosa is the cause of concentrations that linger in saliva. After the troche dissolves, inhibitory amounts might linger in saliva for up to three hours.

Topical:Thereis very little clotrimazole absorbed via healthy skin.
Intravaginal: The absorption rate of this route is between 3 and 10% of the dosage. In roughly 24 hours, vaginal cream achieves its highest serum levels. Approximately 5–10% of clotrimazole is absorbed after vaginal administration. Consequently, for up to three days following administration, fungicidal concentrations may remain in the vagina.

Administration
Strengths and Dosage Forms Available Under a number of FDA-approved trade names, clotrimazole is sold as topical lotions, powders, oral lozenges, and vaginal inserts and tablets.

Transmucosal administration of oral formulations (10 mg) is used. Without chewing, patients should let the troches dissolvegradually in their mouths.Topical cream, ointment, or lotion formulations containing 1% are applied by gently massaging the medication into the skin that has been washed and afflicted. It is not recommended to use these formulation.Intravaginal administration (1% and 2% cream, tablet) is limited to clotrimazole preparations that are specifically designated for intravaginal usage. In certain commercially available treatments, vaginal cream (1%, 2%) and intravaginal pills (200 mg, 500 mg) are combined in a single box. Itching and pain can be relieved by externally applying the intravaginal cream to the vulva, the affected area. You can use the specific applicator that the manufacturer provides. Proper dosage and treatment regimens should be explained to patients.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1587-1602 www.ijprajournal.com ISSN: 2456-4494

During treatment, patients should refrain from using spermicides, douches, or tampons. Additionally, the patient should be instructed to refrain from having sex while undergoing treatment. Condoms, diaphragms, and cervical caps may sustain damage or malfunction as a result of vaginal clotrimazole products.

Adult Dosage

Application vaginally (cream/tablet) for vulvo vaginal candidiasis (VVC)One application of 50 mg of 1% cream or 100 mg of 2% cream should be applied vaginally at bedtime for seven days or three days, respectively. In the event of extra-vaginal symptoms, the cream may also be applied externally.

According to guidelines, patients who are immunocompromised or have complicated infections (such as VCC during pregnancy, recurrent or severe infections, or infections with non-albicans Candida) should receive treatment for seven to fourteen days.

Tablets: Take one 200 mg tablet once a day for three days, or take one 500 mg tablet vaginally at night.

Adverse Effects

Itching, nausea, and vomiting are among of the negative effects of the oral formulation. Abnormal liver function tests may occur in over 10% of patients taking oral clotrimazole (troche). Therefore, liver function tests should be performed on a regular basis for patients taking oral clotrimazole (troche).

Less than 10% of individuals who get clotrimazole for vulvovaginal candidiasis experience burning in the vagina or vulvar region. Rashes, blisters, hives, burning, peeling, stinging, redness, swelling, pain, and other symptoms of skin irritation are examples of further adverse effects. When topical formulations cause irritation or sensitivity at the administration site, they should be used externally and stopped.

Contraindications

Topical clotrimazole is ineffective in treating onychomycosis. Consequently, an oral (systemic) antifungal medication is typically needed to treat fungal nail infections.

Menstruation and contraceptive devices: Throughout the period of treatment, patients should refrain from having sex. Because intravaginal clotrimazole preparations can destroy contraceptive devices such cervical caps, condoms, and diaphragms, contraceptive failures may occur during treatment. Additionally, using a tampon during menstruation is not advised when using clotrimazole.

Individuals who are hypersensitive to azole antifungals should refrain from taking clotrimazole. The ingredients in the formulation that are contained in many clotrimazole products frequently cause hypersensitivity responses.Ocular exposure and ophthalmic administration: Treat right away by washing the afflicted eye with cool, clean water if clotrimazole comes into touch with it. If your eye irritation doesn't go away, see an ophthalmologist.

.

Monitoring

Clotrimazole is applied topically or intravaginally as oral/transmucosal lozenges (troches); it is not intended for systemic administration. Absorbable amounts are broken down in the liver and eliminated in the bile.

Toxicity

Toxic side effects, including pelvic cramps, hives, skin rash, sporadic headache, itching, and irritation of the vulva and vagina, may be seen when clotrimazole is used locally and topically; therapy should be stopped if any of these occur.

Topical Antifungal Uses:

1.Skin infections-ringworm, jockitch, athlete's foot, andtinea infections. Yeast infections-oral thrush, vaginal candidiasis. Nail infections-mild cases of onychomycosis. Scalp infections-Malassezia-induced dandruff (Ketoconazole shampoo).

How Topical Antifungals Are Used

Priorto administering the medication,clean and dry the afflicted area.

Lightly apply the antifungal spray, ointment, orcream.

To avoid recurrence, adhere to the entire course of treatment, which typically lasts 1-4 weeks.

.Unless instructed by a physician, donot cover the area tightly.

Some common fungal infection:

(A). Environmental explosure:

Contact with contaminated surfaces(such as gym equipment or floors) might result in ringworm or athlete's foot. Inhalation of fungal spores–Can lead to lung infections like

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1587-1602 www.ijprajournal.com ISSN: 2456-4494

histoplasmosis or asper gillosis.Moist and warm environments–Encourage fungal growth on the skin(e.g.,candidiasis, ringworm).

(B).Weakened immune system:

HIV/AIDS –Increases the risk of systemic fungal infections like cryptococcosis Cancer treatments (chemotherapy, radiation**)**–Suppress immunity, making fungal infections more likely. Organ transplants and immuno suppressive drugs–Increase susceptibility to infections like candidiasis or aspergillosis.

(C).Poor Hygiene and Lifestyle Factors:

Wearing tight or damp clothing–Creates an ideal environment for fungal growth(e.g., jock itch). Walking b are foot in publicplaces–Canlead to athlete's foot ortoenail fungus.Uncontrolled diabetes–Highblood sugarlevels promote fungal infections, especially Candida infections.

(D)Antibiotic Use:

Over use of antibiotics–Kills beneficial bacteria that normally prevent fungal over growth, leading to yeast infections.High-Risk Groups for Fungal Infections, People with weakened immune systems (HIV/AIDS, cancer patients),Individuals with diabetes,Those who frequently use public showers, gyms, or swimming pools People on long-term antibiotic or corticosteroid us

Topical Antifungals' Adverse Effects:

Dryness, burning, redness, oritching are examples of mild responses, Allergic responses,such as extreme itching or swelling.

Oral Antifungal:

Medication administered orally (astablets, capsules, orliquidsuspensions) to treatmild to severe fungal infections of the skin, nails, mucous membranes, and internal organs is known as an oral antifungal. They function by eithereliminating fungus or preventing their growth.

Mechanism of action:

The way that oral antifungal drugs function varies according on the kind of the drug; the primary classes oforal antifungals areazoles, allylamines,polyenes,and echinocandins.
Azoles(e.g., Fluconazole, Itraconazole, Ketoconazole, Voriconazole)

Mechanism:

Inhibit lanostero l14α-demethylase, akeyenzymeiner gosterol synthesis (a crucial component of fungal cell membranes).

Effect:Depletesergosterol, leading to increased membrane permeability and fungal cell death. Candida infections, dermatophytosis, systemicmycoses.

Allylamines (e.g.,Terbinafine,Naftifine)
Mechanism:Inhibit squal eneepoxidase, another key enzymeiner gosterol synthesis.
Effect: Accumulation of toxic squalene and depletion of ergosterol, leading to fungal cell death. These are mostly use Dermatophyte infections (e.g.,tineapedis, tineacorporis, onychomycosis).

Polyenes(e.g., Nystatin, Amphoteric in B-though usually IV)
Mechanism: Bindtoer gosterol in fungal cell membranes, creating pores that cause leakage of ions and cellular components.
Effect: Disrupts fungal cellintegrity, leading to cell death. These are mostly used Candidiasis (Nystatin for oral thrush).

Echinocandins (e.g.,Caspofungin, Micafungin)
Rarelyoral Mechanism: In hibit β-1,3-glucan synthase, preventing fungal cell wall synthesis. Effect: Weakens fungal cell walls, causing osmotic instability and cell lysis.These are mostly use Systemic Candida and Aspergillus infections (IV forms are used).

Drugs:
Itraconazol:

Numerous fungal infections can be treated with itraconazole. Even while many of these fungal diseases are uncommon, they can nevertheless harm those with weakened immune systems. The FDA has approved itraconazole (often shortened to ITZ) as a treatment for aspergillosis, blastomycosis, and histoplasmosis. Nevertheless, itraconazole has also demonstrated effectiveness in treating candidiasis, coccidioidomycosis, and paracoccidioidomycosis; nevertheless, the FDA has not approved it for these disorders.Apart from treating infections, itraconazole can also be used to prevent these systemic fungal infections in people who are at risk. Patients with HIV, individuals undergoing chemotherapy, and organ transplant recipients are among the patient groups who commonly utilize itraconazole prophylaxis.Because of its broad-spectrum coverage, safety profile, and low level of fungal resistance, itraconazole

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1587-1602 www.ijprajournal.com ISSN: 2456-4494

provides these immunocompromised individuals with good prophylactic protection.Itraconazole is approved by the FDA to treat superficial fungal infections, such as onychomycosis, in addition to systemic diseases. However, only 63% of cases of onychomycosis can be cured with itraconazole therapy. Although the FDA has not approved this use, itraconazole can also be used to treat various topical mycoses and moderate to severe seborrheic dermatitis. Topical steroids and antifungal shampoos are first-line treatments for seborrheic dermatitis, even though itraconazole is an excellent treatment. Itraconazole is provided as a pulse therapy for seborrheic dermatitis, which means that high dosages of the medication are given sporadically to prevent adverse effects while yet producing the desired therapeutic results.

Mechanism of Action

A broad-spectrum antifungal drug, itraconazole has an active metabolite called hydroxyitraconazole. Ergosterol synthesis is inhibited by itraconazole, which aids in the maintenance of the fungal cell membrane. Fungal 14 alpha-demethylase catalyzes the 14 alpha-demethylation process that converts lanosterol to ergosterol. Through its interaction with the substrate-binding site of fungal 14 alpha-demethylase, itraconazole inhibits this process. Fungal membrane irregularities brought on by this compromised ergosterol synthesis alter membrane-bound enzyme activity by increasing permeability and rupturing the integrity of fungal cell membranes.The medicine undergoes substantial CYP450 system metabolism; in particular, itraconazole is a substrate of CYP3A4. Its half-life is between 34 and 42 hours. 35% of the medication is eliminated through urine, while 3–18% is eliminated through feces.

Administration

Itraconazole is available as an oral solution (10 mg/mL), intravenous (10 mg/mL), or capsule (100 mg), allowing for both inpatient and outpatient administration of the medication.Due to individual differences in gastric acid conditions and intestinal epithelial injury, the absorption of itraconazole through the capsule varies greatly. However, the drug's most recent formulations, such as oral and intravenous preparations including hydroxypropyl-beta-cyclodextrin, have demonstrated improved bioavailability and absorption.

The following is the FDA-approved dosage by indication:

Onychomycosis of the Fingernails:

Take 200 mg twice a day in capsule form for seven days, then take a 21-day break. Provide immuno 'compromised patients with two courses.

Fungal Infection:

200 mg taken orally every day or twice a day in capsule form; in cases of life-threatening infections, begin taking 200 mg twice a day for three days. 600 mg per day is the maximum dosage. Give 200 mg daily in divided doses with meals.

Onychomycosis of the Toenails:

For 12 weeks, take 200 mg daily orally (in capsules).

Candidiasis:

Oropharyngeal: Swish and swallow 20 mL taken orally for 1–2 weeks. Oral administration of 10 mL twice a day for 2–4 weeks is an alternative.

For 14–21 days, take 20 mL orally twice a day.

Blastomycosis:

200 mg orally daily (capsules); maximum dose 400 mg daily; if no therapeutic response occurs, pulmonary and extrapulmonary diseases may increase dosage by 100 mg increments; doses above 200 mg daily may be divided; daily maximum 600 mg.

Histoplasmosis:

200 mg taken orally daily in pill form; 400 mg daily is the maximum dosage. If there is no therapeutic response, the dosage can be increased by 100 mg increments; doses beyond 200 mg should be divided daily.

Invasive Aspergillosis:

Give the patient 20 mL orally every 12 hours or 200–400 mg daily (in capsule form); divide doses above 200 mg daily. The patient can also take the oral solution without food and the capsules with meals.

Adverse Effects

Although itraconazole is a reasonably safe drug, using it can have certain negative side effects. Cardiotoxicity is an uncommon side consequence. Itraconazole can lower the left ventricular ejection fraction and heart contractility. A intake of more than 400 mg per day raises the risk of

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1587-1602 www.ijprajournal.com ISSN: 2456-4494

cardiotoxicity. While most patients' heart function improves after discontinuing itraconazole, others require a transplant.Hepatotoxicity, which frequently manifests as a reversible rise in aminotransferase levels, is another negative consequence. Short-term or sporadic doses can minimize this negative effect. Itraconazole can result in resistant hypertension in persons who are currently receiving treatment for hypertension.Gastrointestinal problems, including nausea, moderate diarrhea, vomiting, and stomach discomfort, are the most frequent side effects. Researchers found that between 2 and 39% of patients who had taken itraconazole experienced these side effects.Additionally, there is a chance of injection site reactions, headaches, and rash when itraconazole is administered intravenously.

Contra indications

The usage of itraconazole has several contraindications. Due to the possible cardiotoxic consequences of itraconazole, the primary one is heart failure or a history of heart failure. Because itraconazole can cause hepatotoxicity, liver disease or failure is another contraindication. Pregnant patients should not take itraconazole either. It has demonstrated teratogenic and embryotoxic effects in animal studies. Researchers found itraconazole to cause eye defects in babies whose mothers had exposure to the drug during pregnancy in a systematic review.Like many other medications, itraconazole is processed by cytochrome P450 (particularly CYP3A4) in the liver, which increases the risk of several drug-drug interactions. Patients on cisapride, astemizole, terfenadine, or itraconazole, for instance, may experience severe heart rhythm abnormalities. Clinicians should refrain from using itraconazole in combination with midazolam and triazolam because it can extend their sedative effects. Additionally, itraconazole can intensify the effects of oral antidiabetic medications, potentially leading to severe hypoglycemia. When administering itraconazole, drug-drug interactions must be taken into account, particularly if the liver metabolizes the other medications using the same cytochrome enzyme.

Monitoring

For the treatment and prevention of fungal infections, itraconazole's trough concentration should be between 0.5 and 1.0 mg/L. The drug's lowest concentration right before the next dose is known as the trough concentration. Patients should see their doctor frequently to make sure that no side effects are developing because itraconazole usually requires a lengthy maintenance treatment period. The concentration of itraconazole should be checked after a week of use and at regular intervals afterward. The drug concentration requires monitoring if the dose of itraconazole changes or if the prescriber adds a medication to a patient's regimen metabolized by the same liver enzyme as itraconazole.

To rule out problems with compliance or unexpected changes in pharmacokinetics, routine monitoring can be helpful. To make sure there is no hepatotoxicity, patients should have their liver enzymes examined on a regular basis in addition to their medication concentration. For patients with hepatic impairment or if treatment lasts longer than a month, LFTs should be obtained at baseline and then at regular intervals.

Toxicity

Itraconazole toxic trough values exceed 3 mcg/mL. No particular antidote is available.

Oral antifungal uses

Terbinafin eand itraconazole for nail infections(onychomycosis).Skin infections (Jockitch, athlete's foot, ringworm) Terbinafine with Griseofulvin. Fluconazole for yeast infections (oralthrush, vaginal candidiasis, and esophageal candidiasis).Itraconazole and amphotericin B (IV for severe cases) for lung and systemic infections (aspergillosis, histoplasmosis, and cryptococcal meningitis)

Howto Take Oral Antifungals Take with or without food, depending on the medication instructions.

Complete the full course (ranging from a few days to months, depending on the infection). Avoid alcohol when taking some antifungals (e.g., Ketoconazole, Griseofulvin).

Side Effects of Oral Antifungals

Nausea, diarrhea, headache, rash, Livertoxicity, heart rhythmissues, Can interact with blood thinners, statins,and other medications.

Intravenous Antifungal:

Antifungal drugs that are injected directly into the blood stream through aveinare known as intravenous (IV) antifungals. They are used to treat serious, potentially fatal fungal infections that oral or topical antifungals are unable to cure.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1587-1602 www.ijprajournal.com ISSN: 2456-4494

Mechanismofaction:

Azoles(e.g., Fluconazole, Voriconazole, Posaconazole, Isavuconazole)

Mechanism: Inhibit lanostero l14α-demethylase, an enzyme involved in ergosterol synthesis (essential for fungal cell membrane integrity).

Effect: Depleteser gosterol, leading to increased membrane permeability and fungal cell death.These are mostly use Systemic Candida infections, cryptococcosis, aspergillosis, and other invasive fungal infections.

Echinocandins(e.g., Caspofungin, Micafungin, Anidulafungin)

Mechanism: Inhibit β-1,3-glu can synthase, which is essential for fungal cell wall synthesis.

Effect: Weakensthe cellwall, leading too smotic instability and fungal cell death. These are mostly used Invasive candidiasis and aspergillosis, especially in critically illorneutropenic patients.

Polyenes(e.g., Amphotericin B, Liposomal Amphoteric in B)

Mechanism: Binds to ergosterol in the fungal cell membrane, for mingpores that cause leakage of cellular contents (ions, proteins).

Effect: Disrupts membrane integrity, leading to fungal cell death. These are mostly used Severe systemic fungal infections like cryptococcal meningitis, mucormycosis, histoplasmosis, and aspergillosis.

Drugs:

Griseofulvin:

Although itraconazole and terbinafine are now more often used treatments for adult tinea capitis, griseofulvin is still the FDA-approved medication of choice for this condition.Because of its affordability and convenience, it is the drug most frequently given to treat tinea capitis in children. Researchers discovered that terbinafine and griseofulvin had the highest clinical and total cure rates among antifungal treatments for tinea capitis.Grizeofulvin treated Microsporum better than Trichophyton in the same research. It is important to remember, nevertheless, that Trichophyton tonsurans is the most frequent cause of tinea capitis in the US. Using griseofulvin in conjunction with selenium sulfide shampoo increases its effectiveness.Griseofulvin is also recommended for onychomycosis, but it has mostly been superseded by more recent antifungals like terbinafine, itraconazole, and fluconazole. Onychomycosis is mostly caused by T. rubrum and T. interdigitale. Excellent evidence suggests that it is a successful treatment for onychomycosis in terms of both clinical and mycologic cures when compared to a placebo. The rate at which nails grow determines how treatment is administered. Because they grow more slowly than fingernails—sometimes taking up to 12 to 18 months to reach full growth—toenails have a lower success rate with treatment. Treatment success may be aided by nail debridement.With the exception of tinea capitis, for which griseofulvin is first-line, as previously stated, it can also treat superficial fungal infections that are not responsive to topical antifungal drug treatment. In youngsters, it is typically the first-line option for this reason. It can be applied by practitioners to both diffuse and severe superficial fungal infections. Tinea manuum, tinea unguium, tinea corporis, and tinea cruris are a few examples of these illnesses.

Mechanism of Action

Griseofulvin inhibits the assembly of microtubules. It influences the development of the mitotic spindle by interacting with microtubules. In dermatophytes, this interference eventually prevents mitosis. Grizeofulvin inhibits the growth of Trichophyton, Microsporum, and Epidermophyton species through this method.Notably, it does not work to cure chromomycosis, yeast (Malassezia, Candida), or dimorphic fungi. Griseofulvin must be taken over a long period of time to be effective because it is rapidly removed from the body.

Administration

Griseofulvin is an oral medication. It comes in microsize (250 and 500 mg tablets) and ultra micro-size (125 and 250 mg tablets) forms. Ultra micro-size tablets are absorbed better than microsize. Griseofulvin is poorly soluble in water. Griseofulvin is best taken with a high-fat meal to increaseabsorption from the GI tract. The duration of therapy is long (e.g., 6 to 12 weeks for tinea capitis), potentially leading to non-compliance. It is also available in a liquid suspension formulation. Each of these medications should be taken daily for the indicated duration and continued until the patient is clinically asymptomatic.

Microsize Dosing

For onychomycosis, take 1000 mg once or four times a day. Fingernails last four months, whereas toenails last six months.

Tinea pedis: 1000 mg once or four times a day for

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1587-1602 www.ijprajournal.com ISSN: 2456-4494

4–8 weeks, along with a topical antifungal medication.500 mg once or four times a day for two to four weeks to treat tinea corporis/cruris
Tinea capitis: 500 mg daily divided from once to four times a day for 4 to 6 weeks.
For four to eight weeks, take 500 mg of tinea barbae once or four times a day.

Ultramicrosize Dosing
375 mg once or three times a day for two to four weeks (for tinea capitis, barbae, corporis, or cruris) or four to six weeks (for tinea capitis).

Adverse Effects

Grizeofulvin has little side effects overall. It most frequently results in headaches, allergic responses, and gastrointestinal problems such nausea, vomiting, and diarrhea.Additional side effects include urticaria, petechiae, pruritus, photosensitivity, and fixed drug eruption. It might make porphyria or lupus worse.

Griseofulvin interacts with drugs that metabolize through the P-450 pathway because it induces cytochrome P-450. Warfarin is one such medication. The anticoagulant action of warfarin is diminished when combined with griseofulvin.Furthermore, griseofulvin may result in a disulfiram-like reaction and intensify the effects of alcohol.

A study involving 295 children, 79 (or 26.8%) experienced mild to moderate adverse effects, with the most common being gastrointestinal. These included elevated triglycerides (1/79), anemia (2/79), SGOT (serum glutamic-oxaloacetic transaminase; 1/79), rash (1/79), abdominal pain (10/79), diarrhea (7/79), dyspepsia (3/79), fever (1/79), headache (12/79), nausea (9/79), weight gain (3/79), vomiting (12/79), and other unspecified events (17/79).[2] All of these adverse effects were transient, and none were considered severe.

Contra indications

Known to cause fetal abnormalities in rats and dogs, as well as conjoined twins in women taking it during the first trimester of pregnancy, griseofulvin is classified as a pregnancy Category C medication. Patients should wait at least one month after finishing treatment with griseofulvin before becoming pregnant.Physicians should not prescribe griseofulvin to anyone who has a hypersensitivity to any part of the medication. Patients with hepatic failure and those diagnosed with porphyria cutanea tarda are also contraindications.

Monitoring

Some healthcare providers who prescribe griseofulvin are concerned about the potential benefits of monitoring alanine aminotransferase (ALT), aspartate aminotransferase (AST), and complete blood count (CBC) with differential. A large retrospective study conducted in adults and children taking griseofulvin or terbinafine for dermatophyte infections shed light on this issue, finding that the majority of laboratory test result abnormalities were low-grade and did not necessitate stopping the medication or doing another laboratory evaluation. Elevations in ALT, AST, anemia, lymphopenia, and neutropenia were all rare and comparable to baseline rates of abnormalities, suggesting that interval laboratory testing is not necessary in both adults and children taking griseofulvin for dermatophyte infections.

Uses of iv antifungal:

Severe blood stream infections (Candidemia, Cryptococcal meningitis), Deep organ fungal infections (Lung, brain, liver, or boneinfections)**,** Fungal pneumonia (Aspergillosis, Histoplasmosis), Severe infections in immunocompromised patients (HIV/AIDS, chemotherapy, organ transplant patients)

How IV Antifungals Are Given:

- Administered in hospitals or under medical supervision.
- Dosage and duration depend on the type and severity of the infection (can last weeks to months).

Side Effects of IV Antifungals
Common Side Effects:

Fever, chills, nausea, headache, Kidney toxicity (especially with Amphotericin B), Liverdamage, Electrolyteim balances, Infusion reactions(chills, fever, rapidheartbeat)

II. CONCLUSION:

From minor infections like ringworm and candidiasis to serious systemic infections like aspergillosis and cryptococcosis, antifungal disorders are brought on by pathogenic fungi. Particularly among immunocompromised people, such as those with HIV/AIDS, cancer, or receiving immunosuppressive treatment, these illnesses provide serious health hazards.Timely diagnosis, efficient antifungal treatment, and treating

underlying medical problems are essential for the clinical management of antifungal disorders. The need for further research, better diagnostics, and the creation of novel therapies is highlighted by the rising incidence of drug-resistant fungus strains and the scarcity of antifungal medications.

REFERENCES:

[1]. Pianalto, K.; Alspaugh, J.A. New Horizons in Antifungal Therapy. J. Fungi 2016, 2, 26. [CrossRef]

[2]. Hidden Crisis: How 150 People Die Every Hour from Fungal Infection While the World Turns a Blind Eye. Available online: https://www.ga .org/wp-content/uploads/GAFFI-Leaflet-June-2016-DWD-hidden-crisis. pdf (accessed on 3 March 2020).

[3]. Pianalto, K.; Alspaugh, J.A. New Horizons in Antifungal Therapy. J. Fungi 2016, 2, 26. [CrossRef]

[4]. Bongomin, F.; Gago, S.; Oladele, R.O.; Denning, D.W. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision. J. Fungi 2017, 3, 57. [CrossRef]

[5]. Prakash, H.; Chakrabarti, A. Global Epidemiology of Mucormycosis. J. Fungi 2019, 5, 26. [CrossRef]

[6]. Pianalto, K.; Alspaugh, J.A. New Horizons in Antifungal Therapy. J. Fungi 2016, 2, 26. [CrossRef]Brown, G.D.; Denning, D.W.; Gow, N.; Levitz, S.M.; Netea, M.; White, T.C. Hidden Killers: Human Fungal Infections. Sci. Transl. Med. 2012, 4, 165rv13. [CrossRef]

[7]. Brown, G.D.; Denning, D.W.; Gow, N.; Levitz, S.M.; Netea, M.; White, T.C. Hidden Killers: Human Fungal Infections. Sci. Transl. Med. 2012, 4, 165rv13. [CrossRef]

[8]. Nucci, M.; Anaissie, E. Fusarium Infections in Immunocompromised Patients. Clin. Microbiol. Rev. 2007, 20, 695–704. [CrossRef]

[9]. Carmona, E.M.; Limper, A.H. Overview of Treatment Approaches for Fungal Infections. Clin. Chest Med. 2017, 38, 393–402. [CrossRef]

[10]. Kumar, A.; Zarychanski, R.; Pisipati, A.; Kumar, A.; Kethireddy, S.; Bow, E.J. Fungicidal versus fungistatic therapy of invasiveCandidainfection in non-neutropenic adults: A meta-analysis. Mycology 2018, 9, 116–128. [CrossRef]

[11]. Meletiadis, J.; Antachopoulos, C.; Stergiopoulou, T.; Pournaras, S.; Roilides, E.; Walsh, T.J. Di erential Fungicidal Activities of Amphotericin B and Voriconazole against Aspergillus Species Determined by Microbroth Methodology. Antimicrob. Agents Chemother. 2007, 51, 3329–3337. [CrossRef]

[12]. Geißel, B.; Loiko, V.; Klugherz, I.; Zhu, Z.; Wagener, N.; Kurzai, O.; Hondel, C.A.M.J.J.V.D.; Wagener, J. Azole-induced cell wall carbohydrate patches kill Aspergillus fumigatus. Nat. Commun. 2018, 9, 3098. [CrossRef]

[13]. Patil, A.; Majumdar, S. Echinocandins in antifungal pharmacotherapy. J. Pharm. Pharmacol. 2017, 69, 1635–1660. [CrossRef]

[14]. Carmona, E.M.; Limper, A.H. Overview of Treatment Approaches for Fungal Infections. Clin. Chest Med. 2017, 38, 393–402. [CrossRef]

[15]. Revie, N.M.; Iyer, K.R.; Robbins, N.; Cowen, L. Antifungal drug resistance: Evolution, mechanisms and impact. Curr. Opin. Microbiol. 2018, 45, 70–76. [CrossRef]

[16]. TenThreats to Global Health in 2019. Available online: https://www.who.int/emergencies/ten-threats-to global-health-in-2019 (accessed on 3 June 2019).

[17]. Ahmad, S.; Bhattacharya, D.; Kar, S.; Ranganathan, A.; Van Kaer, L.; Das, G. Curcumin Nanoparticles Enhance Mycobacterium bovis BCG Vaccine E cacybyModulating Host ImmuneResponses. Infect. Immun. 2019, 87, 1–33. [CrossRef]

[18]. Scriven, J.E.; Tenforde, M.W.; Levitz, S.M.; Jarvis, J.N. Modulating host immune responses to fight invasive fungal infections. Curr. Opin. Microbiol. 2017, 40, 95–103. [CrossRef]

[19]. Scriven, J.E.; Tenforde, M.W.; Levitz, S.M.; Jarvis, J.N. Modulating host immune responses to fight invasive fungal infections. Curr. Opin. Microbiol. 2017, 40, 95–103. [CrossRef]

[20]. Nerva, L.; Chitarra, W.; Siciliano, I.; Gaiotti, F.; Ciu o, M.; Forgia, M.; Varese, G.C.; Turina, M. Mycoviruses mediate mycotoxin regulation in Aspergillus ochraceus. Environ. Microbiol. 2018, 21,

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1587-1602 www.ijprajournal.com ISSN: 2456-4494

1957–1968. [CrossRef
[21]. Ahmad, S.; Bhattacharya, D.; Kar, S.; Ranganathan, A.; Van Kaer, L.; Das, G. Curcumin Nanoparticles Enhance Mycobacterium bovis BCG Vaccine E cacybyModulating Host ImmuneResponses. Infect. Immun. 2019, 87, 1–33. [CrossRef]
[22]. Scriven, J.E.; Tenforde, M.W.; Levitz, S.M.; Jarvis, J.N. Modulating host immune responses to fight invasive fungal infections. Curr. Opin. Microbiol. 2017, 40, 95–103. [CrossRef]
[23]. Hamill, R.J. Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity. Drugs 2013, 73, 919–934
[24]. Vermes, A.; Guchelaar, H.-J.; Dankert, J. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 2000, 46, 171–179]
[25]. Crowley PD, Gallagher HC. Clotrimazole as a pharmaceutical: past, present and future. J Appl Microbiol. 2014 Sep;117(3):611-7. [PubMed] [Reference list]
[26]. Woo TE, Somayaji R, Haber RM, Parsons L. Diagnosis and Management of Cutaneous Tinea Infections. Adv Skin Wound Care. 2019 Aug;32(8):350-357. [PubMed] [Reference list]
[27]. Kalra MG, Higgins KE, Kinney BS. Intertrigo and secondary skin infections. Am Fam Physician. 2014 Apr 01;89(7):569-73. [PubMed] [Reference list].
[28]. Hitchcock CA, Dickinson K, Brown SB, Evans EG, Adams DJ. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans. Biochem J. 1990 Mar 01;266(2):475-80. [PMC free article] [PubMed] [Reference list]
[29]. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, andcorrelation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999 Oct;12(4):501-17. [PMC free article] [PubMed] [Reference list]
[30]. Bartolommei G, Tadini-Buoninsegni F, Hua S, Moncelli MR, Inesi G, Guidelli R. Clotrimazole inhibits the Ca2+-ATPase (SERCA) by interfering with Ca2+ binding and favoring the E2 conformation. J Biol Chem. 2006 Apr 07;281(14):9547-51. [PubMed] [Reference list].
[31]. Jelen G, Tennstedt D. Contact dermatitis from topical imidazole antifungals: 15 newcases. Contact Dermatitis. 1989 Jul;21(1):6-11. [PubMed] [Reference list]
[32]. Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant. 2001 Apr;15(2):95-9. [PubMed] [Reference list]
[33]. Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs. 2001;61 Suppl 1:39-47. [PubMed] [Reference list]
[34]. Piérard GE, Arrese JE, Piérard-Franchimont C. Itraconazole. Expert Opin Pharmacotherapy. 2000 Jan;1(2):287-304. [PubMed] [Reference list]
[35]. Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther. 2001 Jun;26(3):159-69. [PubMed] [Reference list]
[36]. Westerberg DP, Voyack MJ. Onychomycosis: Current trends in diagnosis and treatment. Am Fam Physician. 2013 Dec 01;88(11):762-70. [PubMed] [Reference list]
[37]. Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2014 Jan;28(1):16-26. [PubMed] [Reference list]
[38]. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001;61 Suppl 1:2737. [PubMed] [Reference list]
[39]. Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs. 2001;61 Suppl 1:39-47. [PubMed] [Reference list]
[40]. Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther. 2001 Jun;26(3):159-69. [PubMed] [Reference list]
[41]. Abraham AO, Panda PK. Itraconazole Induced Congestive Heart Failure, A Case

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1587-1602 www.ijprajournal.com ISSN: 2456-4494

Study. Curr Drug Saf. 2018;13(1):59-61. [PubMed] [Reference list]

[42]. Denolle T, Azizi M, Massart C, Zennaro MC. [Itraconazole: a new drug-related cause of hypertension]. Ann Cardiol Angeiol (Paris). 2014 Jun;63(3):213-5. [PubMed] [Reference list]

[43]. Piérard GE, Arrese JE, Piérard-Franchimont C. Itraconazole. Expert Opin Pharmacother. 2000 Jan;1(2):287-304. [PubMed] [Reference list]

[44]. Liu D, Zhang C, Wu L, Zhang L, Zhang L. Fetal outcomes after maternal exposure to oral antifungal agents during pregnancy: A systematic review and meta-analysis. Int J Gynaecol Obstet. 2020 Jan;148(1):6-13. [PMC free article] [PubMed] [Reference list]

[45]. Piérard GE, Arrese JE, Piérard-Franchimont C. Itraconazole. Expert Opin Pharmacother. 2000 Jan;1(2):287-304. [PubMed] [Reference list]

[46]. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014 May;69(5):1162-76. [PMC free article] [PubMed] [Reference list]

[47]. Piérard GE, Arrese JE, Piérard-Franchimont C. Itraconazole. Expert Opin Pharmacother. 2000 Jan;1(2):287-304. [PubMed] [Reference list]

[48]. Kably B, Launay M, Derobertmasure A, Lefeuvre S, Dannaoui E, Billaud EM. Antifungal Drugs TDM: Trends and Update. Ther Drug Monit. 2022 Feb 01;44(1):166-197. [PubMed] [Reference list]

[49]. Elghblawi E. Tinea Capitis in Children and Trichoscopic Criteria. Int J Trichology. 2017 Apr-Jun;9(2):47-49. [PMC free article] [PubMed] [Reference list]

[50]. Gupta AK, Mays RR, Versteeg SG, Piraccini BM, Shear NH, Piguet V, Tosti A, Friedlander SF. Tinea capitis in children: a systematic review of management. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2264-2274. [PubMed] [Reference list]

[51]. Kreijkamp-Kaspers S, Hawke K, Guo L, Kerin G, Bell-Syer SE, Magin P, Bell-Syer SV, van Driel ML. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017 Jul 14;7(7):CD010031. [PMC free article] [PubMed] [Reference list]

[52]. Gupta AK, Foley KA, Versteeg SG. New Antifungal Agents and New Formulations Against Dermatophytes. Mycopathologia. 2017 Feb;182(1-2):127-141. [PubMed] [Reference list]

[53]. Gupta AK, Daigle D, Foley KA. Topical therapy for toenail onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014 Dec;15(6):489-502. [PubMed] [Reference list]

[54]. Gupta AK, Mays RR, Versteeg SG, Piraccini BM, Shear NH, Piguet V, Tosti A, Friedlander SF. Tinea capitis in children: a systematic review of management. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2264-2274. [PubMed] [Reference list]

[55]. Gupta AK, Mays RR, Versteeg SG, Piraccini BM, Shear NH, Piguet V, Tosti A, Friedlander SF. Tinea capitis in children: a systematic review of management. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2264-2274. [PubMed] [Reference list]

[56]. Gupta AK, Mays RR, Versteeg SG, Piraccini BM, Shear NH, Piguet V, Tosti A, Friedlander SF. Tinea capitis in children: a systematic review of management. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2264-2274. [PubMed] [Reference list]

[57]. Kreijkamp-Kaspers S, Hawke K, Guo L, Kerin G, Bell-Syer SE, Magin P, Bell-Syer SV, van Driel ML. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017 Jul 14;7(7):CD010031. [PMC free article] [PubMed] [Reference list]

[58]. Chaudhary RG, Rathod SP, Jagati A, Zankat D, Brar AK, Mahadevia B. Oral Antifungal Therapy: Emerging Culprits of Cutaneous Adverse Drug Reactions. Indian Dermatol Online J. 2019 Mar-Apr;10(2):125-130. [PMC free article] [PubMed] [Reference list]

[59]. Blank H. The actions and interactions of drugs: the therapeutic significance of enzyme induction. Trans St Johns Hosp Dermatol Soc. 1967;53(1):1-23. [PubMed]

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1587-1602 www.ijprajournal.com ISSN: 2456-4494

[Reference list]

[60]. Katz HI. Systemic antifungal agents used to treat onychomycosis. J Am Acad Dermatol. 1998 May;38(5 Pt 3):S48-52. [PubMed] [Reference list]

[61]. Smith EB. The treatment of dermatophytosis: safety considerations. J Am Acad Dermatol. 2000 Nov;43(5 Suppl):S113-9. [PubMed] [Reference list]

[62]. Spiro JM, Demis DJ. The effects of griseofulvin on porphyria cutanea tarda. J Invest Dermatol. 1968 Mar;50(3):202-7. [PubMed] [Reference list]

[63]. Stolmeier DA, Stratman HB, McIntee TJ, Stratman EJ. Utility of Laboratory Test Result Monitoring in Patients Taking Oral Terbinafine or Griseofulvin for Dermatophyte Infections. JAMA Dermatol. 2018 Dec 01;154(12):1409-1416. [PMC free article] [PubMed] [Reference list]

[64]. Brown, G.D.; Denning, D.W.; Gow, N.; Levitz, S.M.; Netea, M.; White, T.C. Hidden Killers: Human Fungal Infections. Sci. Transl. Med. 2012, 4, 165rv13. [CrossRef]

[65]. Hamill, R.J. Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity. Drugs 2013, 73, 919–934

[66]. Bartolommei G, Tadini-Buoninsegni F, Hua S, Moncelli MR, Inesi G, Guidelli R. Clotrimazole inhibits the Ca2+-ATPase (SERCA) by interfering with Ca2+ binding and favoring the E2 conformation. J Biol Chem. 2006 Apr 07;281(14):9547-51. [PubMed] [Reference list].

[67]. Vermes, A.; Guchelaar, H.-J.; Dankert, J. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 2000, 46, 171–179]

[68]. Crowley PD, Gallagher HC. Clotrimazole as a pharmaceutical: past, present and future. J Appl Microbiol. 2014 Sep;117(3):611-7. [PubMed] [Reference list]

[69]. Woo TE, Somayaji R, Haber RM, Parsons L. Diagnosis and Management of Cutaneous Tinea Infections. Adv Skin Wound Care. 2019 Aug;32(8):350-357. [PubMed] [Reference list]

[70]. Kalra MG, Higgins KE, Kinney BS. Intertrigo and secondary skin infections. Am Fam Physician. 2014 Apr 01;89(7):569-73. [PubMed] [Reference list].

[71]. Hitchcock CA, Dickinson K, Brown SB, Evans EG, Adams DJ. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans. Biochem J. 1990 Mar 01;266(2):475-80. [PMC free article] [PubMed] [Reference list]

[72]. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999 Oct;12(4):501-17. [PMC free article] [PubMed] [Reference list]

[73]. Bartolommei G, Tadini-Buoninsegni F, Hua S, Moncelli MR, Inesi G, Guidelli R. Clotrimazole inhibits the Ca2+-ATPase (SERCA) by interfering with Ca2+ binding and favoring the E2 conformation. J Biol Chem. 2006 Apr 07;281(14):9547-51. [PubMed] [Reference list].

[74]. Jelen G, Tennstedt D. Contact dermatitis from topical imidazole antifungals: 15 new cases. Contact Dermatitis. 1989 Jul;21(1):6-11. [PubMed] [Reference list]

[75]. Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant. 2001 Apr;15(2):95-9. [PubMed] [Reference list]

[76]. Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs. 2001;61 Suppl 1:39-47. [PubMed] [Reference list]

[77]. Piérard GE, Arrese JE, Piérard-Franchimont C. Itraconazole. Expert Opin Pharmacotherapy. 2000 Jan;1(2):287-304. [PubMed] [Reference list]

[78]. Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther. 2001 Jun;26(3):159-69. [PubMed] [Reference list]

[79]. Westerberg DP, Voyack MJ. Onychomycosis: Current trends in diagnosis and treatment. Am Fam Physician. 2013 Dec 01;88(11):762-70. [PubMed] [Reference list]

[80]. Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2014 Jan;28(1):16-26. [PubMed] [Reference list]
[81]. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001;61 Suppl 1:2737. [PubMed] [Reference list]
[82]. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001;61 Suppl 1:2737. [PubMed] [Reference list]
[83]. Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs. 2001;61 Suppl 1:39-47. [PubMed] [Reference list]
[84]. Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther. 2001 Jun;26(3):159-69. [PubMed] [Reference list]
[85]. Abraham AO, Panda PK. Itraconazole Induced Congestive Heart Failure, A Case Study. Curr Drug Saf. 2018;13(1):59-61. [PubMed] [Reference list]
[86]. Denolle T, Azizi M, Massart C, Zennaro MC. [Itraconazole: a new drug-related cause of hypertension]. Ann Cardiol Angeiol (Paris). 2014 Jun;63(3):213-5. [PubMed] [Reference list
[87]. Piérard GE, Arrese JE, Piérard-Franchimont C. Itraconazole. Expert Opin Pharmacother. 2000 Jan;1(2):287-304. [PubMed] [Reference list]
[88]. Liu D, Zhang C, Wu L, Zhang L, Zhang L. Fetal outcomes after maternal exposure to oral antifungal agents during pregnancy: A systematic review and meta-analysis. Int J Gynaecol Obstet. 2020 Jan;148(1):6-13. [PMC free article] [PubMed] [Reference list]
[89]. Piérard GE, Arrese JE, Piérard-Franchimont C. Itraconazole. Expert Opin Pharmacother. 2000 Jan;1(2):287-304. [PubMed] [Reference list]
[90]. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014 May;69(5):1162-76. [PMC free article] [PubMed] [Reference list]
[91]. Piérard GE, Arrese JE, Piérard-Franchimont C. Itraconazole. Expert Opin Pharmacother. 2000 Jan;1(2):287-304. [PubMed] [Reference list]
[92]. Kably B, Launay M, Derobertmasure A, Lefeuvre S, Dannaoui E, Billaud EM. Antifungal Drugs TDM: Trends and Update. Ther Drug Monit. 2022 Feb 01;44(1):166-197. [PubMed] [Reference list]
[93]. Elghblawi E. Tinea Capitis in Children and Trichoscopic Criteria. Int J Trichology. 2017 Apr-Jun;9(2):47-49. [PMC free article] [PubMed] [Reference list]
[94]. Gupta AK, Mays RR, Versteeg SG, Piraccini BM, Shear NH, Piguet V, Tosti A, Friedlander SF. Tinea capitis in children: a systematic review of management. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2264-2274. [PubMed] [Reference list]
[95]. Kreijkamp-Kaspers S, Hawke K, Guo L, Kerin G, Bell-Syer SE, Magin P, Bell-Syer SV, van Driel ML. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017 Jul 14;7(7):CD010031. [PMC free article] [PubMed] [Reference list]
[96]. Gupta AK, Foley KA, Versteeg SG. New Antifungal Agents and New Formulations Against Dermatophytes. Mycopathologia. 2017 Feb;182(1-2):127-141. [PubMed] [Reference list]
[97]. Gupta AK, Daigle D, Foley KA. Topical therapy for toenail onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014 Dec;15(6):489-502. [PubMed] [Reference list]
[98]. Gupta AK, Mays RR, Versteeg SG, Piraccini BM, Shear NH, Piguet V, Tosti A, Friedlander SF. Tinea capitis in children: a systematic review of management. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2264-2274. [PubMed] [Reference list]
[99]. Gupta AK, Mays RR, Versteeg SG, Piraccini BM, Shear NH, Piguet V, Tosti A, Friedlander SF. Tinea capitis in children: a systematic review of management. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2264-2274. [PubMed] [Reference list]
[100]. Gupta AK, Mays RR, Versteeg SG, Piraccini BM, Shear NH, Piguet V, Tosti

A, Friedlander SF. Tinea capitis in children: a systematic review of management. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2264-2274. [PubMed] [Reference list]

[101]. Kreijkamp-Kaspers S, Hawke K, Guo L, Kerin G, Bell-Syer SE, Magin P, Bell-Syer SV, van Driel ML. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017 Jul 14;7(7):CD010031. [PMC free article] [PubMed] [Reference list]

[102]. Chaudhary RG, Rathod SP, Jagati A, Zankat D, Brar AK, Mahadevia B. Oral Antifungal Therapy: Emerging Culprits of Cutaneous Adverse Drug Reactions. Indian Dermatol Online J. 2019 Mar-Apr;10(2):125-130. [PMC free article] [PubMed] [Reference list]

[103]. Blank H. The actions and interactions of drugs: the therapeutic significance of enzyme induction. Trans St Johns Hosp Dermatol Soc. 1967;53(1):1-23. [PubMed] [Reference list]

[104]. Katz HI. Systemic antifungal agents used to treat onychomycosis. J Am Acad Dermatol. 1998 May;38(5 Pt 3):S48-52. [PubMed] [Reference list]

[105]. Smith EB. The treatment of dermatophytosis: safety considerations. J Am Acad Dermatol. 2000 Nov;43(5 Suppl):S113-9. [PubMed] [Reference list]

[106]. Spiro JM, Demis DJ. The effects of griseofulvin on porphyria cutanea tarda. J Invest Dermatol. 1968 Mar;50(3):202-7. [PubMed] [Reference list]

[107]. Stolmeier DA, Stratman HB, McIntee TJ, Stratman EJ. Utility of Laboratory Test Result Monitoring in Patients Taking Oral Terbinafine or Griseofulvin for Dermatophyte Infections. JAMA Dermatol. 2018 Dec 01;154(12):1409-1416. [PMC free article] [PubMed] [Reference list]